Halozyme Therapeutics, Inc. (HALO): Stock Offering News

HALO – Commences a public offering of $100 mln of shares of its common stock.


Key Facts Surrounding This News Item


  • HALO had a POWR Rating of B (Buy) coming into today.
  • HALO was -1.90% below its 10-Day Moving Average coming into today.
  • HALO was -1.20% below its 20-Day Moving Average coming into today.
  • HALO was 1.30% above its 50-Day Moving Average coming into today.
  • HALO was 7.82% above its 100-Day Moving Average coming into today.
  • HALO was 16.31% above its 200-Day Moving Average coming into today.
  • HALO had returned +39.27% year-to-date leading up to today’s news, versus a +5.96% return from the benchmark S&P 500 during the same period.

More Info About Halozyme Therapeutics, Inc. (HALO)


Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California. View our full HALO ticker page with ratings, news, and more.

HALO at a Glance

HALO Current POWR Rating™
Overall POWR Rating™
HALO Current Price $11.98 0.67%
More HALO Ratings, Data, and News

HALO Price Reaction

The day of this event (May. 18, 2017)
HALO Closing Price$14.16 2.91%
HALO Volume915,500
39.05% from avg
Leading up to this event
HALO 1-mo return8.09%
After this event
HALO 1-day return6.58%
HALO 3-day return7.92%
HALO 5-day return9.21%

HALO Price Chart



More Halozyme Therapeutics, Inc. (HALO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All HALO News
Page generated in 1.121 seconds.